Octreotide dose for hypoglycemia in patients taking glymepride

Reading File

Finding Sources

Reading File

Here is a summary of octreotide dosing for sulfonylurea (including glimepiride)-induced hypoglycemia, drawn from authoritative emergency medicine textbooks:

Octreotide for Glimepiride-Induced Hypoglycemia

Glimepiride is a sulfonylurea — it stimulates insulin secretion from pancreatic beta cells. Octreotide, a somatostatin analogue, suppresses insulin secretion and is the agent of choice when dextrose alone is insufficient or causes rebound hypoglycemia.

When to Use

After initial glucose/dextrose therapy has been initiated
When response to dextrose is inadequate or recurrent hypoglycemia occurs
Primarily used to reduce the risk of recurrent hypoglycemia (since dextrose can paradoxically stimulate further insulin release from the sulfonylurea effect)

Dosing

Population	Route	Dose	Frequency
Adults	IV or subcutaneous	50–100 mcg	Every 12 hours
Pediatric	IV or subcutaneous	0.1 mcg/kg	Every 12 hours

Key Points

Octreotide is superior to glucose and diazoxide for sulfonylurea-induced hypoglycemia
It does not replace the need for prolonged observation — patients should be monitored for 24 hours given glimepiride's duration of action
Serial blood glucose measurements are mandatory even after octreotide administration
Patients should eat as soon as practical to replete glycogen stores

Sources:

Rosen's Emergency Medicine, Management section (p. 4055)
Tintinalli's Emergency Medicine: A Comprehensive Study (p. 1474)
Harrison's Principles of Internal Medicine 22E, Urgent Treatment of Hypoglycemia

This is a shared conversation. Sign in to Orris to start your own chat.